Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma.

Sommer, Ulrich; Eckstein, Markus; Ammann, Johannes; Braunschweig, Till; Macher-Göppinger, Stephan; Schwamborn, Kristina; Hieke-Schulz, Stefanie; Harlow, Greg; Flores, Mike; Wullich, Bernd; Wirth, Manfred; Roth, Wilfried; Knüchel, Ruth; Weichert, Wilko; Baretton, Gustavo; Hartmann, Arndt

doi:10.1016/j.clgc.2020.02.009

Benutzer: Gast

journal article

Dokumenttyp:: Journal Article
Autor(en):: Sommer, Ulrich; Eckstein, Markus; Ammann, Johannes; Braunschweig, Till; Macher-Göppinger, Stephan; Schwamborn, Kristina; Hieke-Schulz, Stefanie; Harlow, Greg; Flores, Mike; Wullich, Bernd; Wirth, Manfred; Roth, Wilfried; Knüchel, Ruth; Weichert, Wilko; Baretton, Gustavo; Hartmann, Arndt
Titel:: Multicentric Analytical and Inter-observer Comparability of Four Clinically Developed Programmed Death-ligand 1 Immunohistochemistry Assays in Advanced Clear-cell Renal Cell Carcinoma.
Abstract:: BACKGROUND: Previous studies have suggested increased clinical benefit with inhibition of programmed death-ligand 1 (PD-L1)/programmed death-1 in patients with PD-L1-positive locally advanced/metastatic renal cell carcinoma (RCC). We examined the analytical and inter-observer comparability of PD-L1-positivity across 4 clinically developed immunohistochemistry assays in clear-cell RCC (CCRCC). MATERIALS AND METHODS: Randomly selected archived, formalin-fixed, paraffin-embedded nephrectomy specimens from 201 patients with locally advanced CCRCC were screened using VENTANA SP142. From these, 30 cases were selected based on their tumor-infiltrating immune cell (IC) PD-L1 status (PD-L1-IC-positivity of < 1%, 1%-5%, or > 5%; 10 cases each). These cases were stained for PD-L1 using VENTANA SP142 and SP263, and DAKO 22C3 and 28-8, and scored for PD-L1 expression on IC and tumor cells (TC) by trained readers at 5 sites. RESULTS: Adjusted mean percentages of PD-L1-IC-positivity and PD-L1-TC-positivity varied from 4.0% to 4.9% and from 1.3% to 10.7%, respectively, between assays. Inter-assay differences in PD-L1-IC-positivity were small and non-significant (P = .1938 to .9963); for PD-L1-TC-positivity, significant differences were observed between VENTANA SP142 and the other assays (P ≤ .0001) and between VENTANA SP263 and DAKO 28-8 (P = .0248). Intra-class correlation values showed moderate-to-high inter-reader agreement for each assay for PD-L1-IC-positivity and for 3 assays for PD-L1-TC-positivity. CONCLUSIONS: In this first multicenter analytical comparison study of PD-L1 assays in CCRCC, PD-L1-positivity could be assessed reproducibly using all 4 assays for IC and for 3 of the 4 assays for TC.
Zeitschriftentitel:: Clin Genitourin Cancer
Jahr:: 2020
Band / Volume:: 18
Heft / Issue:: 5
Seitenangaben Beitrag:: e629-e642
Volltext / DOI:: doi:10.1016/j.clgc.2020.02.009
PubMed:: http://view.ncbi.nlm.nih.gov/pubmed/32178978
Print-ISSN:: 1558-7673
TUM Einrichtung:: Institut für Allgemeine Pathologie und Pathologische Anatomie
BibTeX

Vorkommen:

mediaTUM Gesamtbestand Hochschulbibliographie 2020 Fakultäten Medizin Institut für Allgemeine Pathologie und Pathologische Anatomie

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments

mediaTUM Gesamtbestand Einrichtungen Schools TUM School of Medicine and Health Departments Preclinical Medicine Institut für Allgemeine Pathologie und Pathologische Anatomie (Dr. Mogler komm.)2020